Thymogen
Published · Researched 2026-09-21
Overview
Thymogen (also Oglufanide, IM-862, "Timogen") is the dipeptide Glu-Trp (L-glutamyl-L-tryptophan), developed under Khavinson's program in the late 1980s and introduced into Russian medical practice in 1990. It is registered in Russia in three dosage forms: intramuscular solution (100 μg/ml), dosed nasal spray (25 μg/dose), and 0.05% cream — an immunomodulator used for prevention/treatment of upper-respiratory viral and bacterial infections, immunodeficiency states, and post-chemo/radiation immune suppression. Its D-amino-acid stereoisomer analog (D-Glu-D-Trp) is the immunosuppressant thymodepressin — the same backbone with opposite immune direction, a nuance community content rarely notes.
Social standing
- Thin 2026 social signal. Thymogen surfaces only as a passing mention inside Khavinson-retrospective educator content (e.g. Peptide Weekly's Aug 2026 "50 years of Russia's peptide program" carousel), not as an independently discussed product. No dedicated Thymogen owner-discussion, anecdotes, or vendor-shill threads were found on Threads, Facebook Groups, or Instagram in this research pass.
- Retailer/educator layer only: peptide-products.com (EU vendor) sells THYMOGEN SPRAY for €35; muscleandbrawn.com hosts a full "complete guide" article framing it as low-toxicity; newsmirror.net runs an "affiliate content" speculative survey. All are commercial or affiliate content, not peer discussion.
- Recurring praise (where mentioned): the only Russian-registered peptide immunomodulator with a nasal-spray form — needle-free delivery; decades of Russian clinical use.
- Recurring complaints/failure modes: near-zero Western owner community; no gray-market vial ecosystem; language barrier of Russian literature.
- Representative quotes: none with attributable peer-owner provenance — marked accordingly.
Social validation
Tier 3 / UNVALIDATED — no two independent social sources with item-level discussion were found. Only Tier-3 signals: educator-retrospective mentions (Peptide Weekly) and commercial/affiliate pages (peptide-products.com, muscleandbrawn.com, newsmirror.net). Community standing cannot be established; the item is included for research completeness, not social demand.
Key specs table
| Property | Value |
|---|---|
| Identity | L-Glu-L-Trp dipeptide (Oglufanide, IM-862) |
| Formula / MW | C16H19N3O5 / 333.34 g/mol |
| CAS | 38101-59-6 (also listed 237068-57-4 — salt form, UNVERIFIED which) |
| Origin | Khavinson program, late 1980s; Russian medical practice since 1990 |
| Mechanism (reported) | Modulates humoral/cellular immunity; normalizes T-lymphocyte (CD3+/CD4+/CD8+) counts and ratios; stimulates IgA/IgG/IgE/IgM production; proposed cAMP/cGMP modulation and AACG DNA-sequence interaction (Russian literature claims, UNVERIFIED in Western trials) |
| Pharma forms (Russia) | IM solution 100 μg/ml; nasal spray 25 μg/dose; 0.05% cream |
| Community-reported dosing | None observed — no community protocols found |
Pricing
- EU retail (observed 2026-09-20): peptide-products.com — THYMOGEN SPRAY €35.00; THYMOPENTIN 10 mg €52.00; THYMOSIN ALPHA 1 3 mg €85.00 (same vendor's immune line).
- Gray-market US: no widely listed Thymogen research vials found (prices UNVERIFIED/unavailable).
- Facebook Marketplace: no used listings observed — say so plainly (none found).
What's included / what's needed
Pharma spray: 10 ml bottle with metered nasal pump (~80+ doses at 25 μg/dose), box with Russian insert. Nothing additional needed. No Western kit ecosystem exists.
Support reality
Distributed through Russian/CIS pharmacies (e.g. Цитомед/«Медико-биологический НПК»); EU vendor peptide-products.com ships the spray with standard retail support. No Western community support infrastructure; buyer guidance is limited to Russian-language labeling.
Community verdict
Thymogen is a footnote in Western peptide culture — known to Khavinson enthusiasts, owned by almost no one. Its one genuine differentiator (a registered nasal-spray immunomodulator with decades of Russian use) is real but undiscussed in English-language social channels. Without community discussion it cannot earn a standing recommendation; it's a research-complete placeholder.
Regulatory & safety status
Registered drug in Russia (three dosage forms, in medical practice since 1990) — NOT FDA-approved, no EMA approval. Gray-market availability outside Russia/CIS is effectively nil; any imported product is unapproved in the buyer's jurisdiction. Safety signals (observed): Russian practice reports rare, mild events — local injection-site reactions, transient nasal irritation; investigated for hepatitis C treatment in the West without reaching approval. Not for human use outside its approved jurisdiction.
Image view breakdown
2/8 views obtained (JPEG, verified 2026-09-20):
- hero: thymogen-hero.jpg (Russian retail photo — Тимоген nasal spray box + bottle, eva.ru listing imagery)
- box: thymogen-box.jpg (Russian retail photo — Тимоген spray box front, zibero.ru listing imagery) Missing views: rear, top, detail, inuse, side, scale — only two distinct real photos found; reused-label risk avoided by honest count.
Not medical advice. This is a research summary of publicly discussed information, not a recommendation to use any substance.
Named sources
- Peptide Weekly — Aug 2026 "50 years of Russia's peptide program" carousel (Aug 2026)
Source URLs were not recorded for these references.